Guardant Health Partners with Nuvalent in Multi-Year Collaboration for Precision Cancer Diagnostics
核心洞察
Guardant Health and Nuvalent announced a multi-year strategic collaboration to develop companion diagnostics for targeted cancer (搜索) therapies using Guardant's tissue and liquid biopsy portfolio.
The partnership will support clinical development of Nuvalent's oncology pipeline targeting ROS1 (搜索)-positive, ALK (搜索)-positive, and HER2 (搜索)-altered non-small cell lung cancer (搜索).
The collaboration reflects the growing importance of biomarker-driven approaches in oncology drug development for identifying appropriate patient populations and improving trial efficiency.
Guardant Health, Inc. (Nasdaq: GH) announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL) to support the development and potential commercialization of Nuvalent's oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platform. The partnership was announced on April 30, 2026, and represents a significant step forward in precision oncology diagnostics.
Strategic Partnership Framework
The collaboration encompasses three key components designed to advance precision medicine in cancer (搜索) treatment. First, Guardant Health will utilize its portfolio of tissue and liquid biopsy tests to support certain Nuvalent global clinical studies. Second, the companies will evaluate opportunities to develop Guardant tissue and/or liquid biopsy assays as companion diagnostics (CDx) to support potential regulatory approvals of Nuvalent's current investigational candidates. Third, both companies will collaborate on the global commercialization of Nuvalent's product candidates, if approved, and Guardant companion diagnostics across major global key markets.
The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations, improving trial efficiency, and supporting regulatory approvals.
Company Profiles and Capabilities
Guardant Health, founded in 2012, is a leading precision oncology company focused on transforming patient care and accelerating new cancer (搜索) therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer (搜索), designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses.
Pipeline Focus Areas
Nuvalent is advancing a robust pipeline with investigational candidates for ROS1 (搜索)-positive, ALK (搜索)-positive, and HER2 (搜索)-altered non-small cell lung cancer (搜索), and multiple discovery-stage research programs. These targeted approaches represent significant opportunities in precision oncology, where companion diagnostics play a crucial role in identifying patients most likely to benefit from specific therapies.
The partnership positions both companies to leverage their complementary expertise in diagnostics and drug development to advance precision medicine approaches in oncology, potentially improving patient outcomes through more targeted treatment strategies.